

Figure S1. Molecular structures of tested compounds (a) ETG-5773, (b) PF-06649298 and (c) BI01383298.



Figure S2. Example data for citrate uptake assay of ETG-5773 (filled circles) with a significant less active analogue ETG-5436 (open circles) considered as a negative control.



Figure S3. Plasma lipid analysis of DIO mice after the 28-day treatment period. (a) plasma cholesterol, (b) plasma triglycerides. Animals were treated orally twice a day with ETG-5773 at 15 mg/kg or with the corresponding vehicle or vehicle in the pair-fed group. ** $p<0.01$ as indicated, ns: non-significant. ANOVA mean SD, n=12 vehicle and ETG-5773, n=8 pair-fed



Figure S4. mRNA expression levels from additional genes involved in hepatic lipogenesis in liver tissue of DIO mice after the 28-day treatment period. Animals were treated orally twice a day with ETG-5773 at 15 mg/kg or with the corresponding vehicle or vehicle in the pair-fed group: (a) mRNA expression of ATP citrate lyase (*ACLY*) gene; (b) mRNA expression of Acetyl CoA carboxylase 1 (*ACC1) gene*; c) mRNA expression of fatty acid synthetase (FASN) * $p<0.05$, ** $p<0.01$ as indicated, ns: non-significant. ANOVA mean SD, n = 12 vehicle and ETG-5773, n=8 pair-fed



Figure S5. Western blot for quantifying adenosine monophosphate-activated protein kinase (AMPK), Thr172 phosphorylated AMPK and ß-actin. Animals were treated orally twice a day with ETG-5773 at 15 mg/kg or with the corresponding vehicle or vehicle in the pair-fed group, n=6 for all groups.